Liotinib is a tyrosine kinase inhibitor primarily indicated for the targeted therapy of certain malignancies. Common adverse reactions include cutaneous manifestations, diarrhea, and fatigue, while severe complications may involve interstitial lung disease, hepatic dysfunction, or cardiovascular disorders. The specific presentation varies among individuals, and patients must adhere strictly to the physician’s instructions for medication administration and undergo regular monitoring.
Common Adverse Reactions and Management Strategies
1. Cutaneous Reactions
Rash, dryness, or pruritus
Mild to moderate cutaneous discomfort occurs in most patients, which can be alleviated with moisturizers, sun avoidance, or the use of mild skin care products.
Hand-foot syndrome
Minimize friction, wear loose-fitting footwear and socks, and dosage adjustment may be required in severe cases.
2. Gastrointestinal Disturbances
Diarrhea, nausea, or anorexia
Mild diarrhea can be relieved by fluid replacement and dietary modifications (e.g., low-fiber diet); contact the physician promptly if symptoms persist or worsen.
Hepatic dysfunction
Manifested as elevated transaminase levels, regular blood tests are required for monitoring, and temporary treatment suspension may be necessary if indicated.
3. Systemic Symptoms
Fatigue and asthenia
Adequate rest is recommended; avoid overexertion and maintain a balanced nutritional intake.
Myalgia or arthralgia
Hot compresses or physical therapy may be used as adjunctive measures; clinical evaluation is required to determine the need for intervention if pain is significant.
Severe Adverse Reactions and Medical Consultation Guidelines
Interstitial lung disease
Rare but potentially life-threatening; immediate treatment discontinuation and medical attention are mandatory.
Cardiovascular disorders
Monitor blood pressure and electrocardiogram regularly; seek immediate medical care if chest pain or palpitations occur.
Severe infection or hemorrhage
Emergency management is required for persistent fever, abnormal ecchymosis, or bleeding episodes.
Precautions
Medication adherence
Dosage should be individualized; do not discontinue treatment or modify the regimen without physician approval.
Drug interactions
Inform the physician of all concurrent medications (e.g., anticoagulants, immunosuppressants) to avoid the risk of interactions.
Special populations
Pregnant women, lactating females, or patients with hepatic or renal insufficiency require careful evaluation of treatment safety.
If any abnormal symptoms develop during treatment, contact the physician promptly, complete relevant examinations, and adjust the treatment regimen if necessary.
